DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) (“DiagnosTear” or the “Company”), a fast-growing innovator in ...
BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted ...